AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00960817
Drug: Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06027983
Drug: Chimeric receptor T-cells + Trastuzumab
RxNorm normalized name: B7-H3-specific chimeric antigen receptor T cells
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
Trial: NCT06027983
Drug: Fludarabine and Cyclophosphosphamide
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
Trial: NCT05513976
Drug: febuxostat tablet
RxNorm normalized name: Febuxostat Tablets
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: febuxostat tablet 40mg or 60mg or 80mg based on prior medication
Trial: NCT06454968
Drug: Orelabrutinib, obinutuzumab, lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
Trial: NCT06010667
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With or without Envafolimab
Trial: NCT04885049
Drug: Racecadotril
RxNorm normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti secretary
Trial: NCT05926206
Drug: Devimistat
RxNorm normalized name: Devimistat
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
Trial: NCT06316323
Drug: Silver diamine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
Trial: NCT06316323
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
Trial: NCT04848974
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04848974
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given SC
Trial: NCT04848974
Drug: Uproleselan
RxNorm normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06171152
Drug: Liraglutide Pen Injector [Saxenda]
RxNorm normalized name: liraglutide Pen Injector [Saxenda]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
Trial: NCT04797286
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
Trial: NCT06251388
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
Trial: NCT05383677
Drug: Anifrolumab
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Trial: NCT05476003
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).
Trial: NCT05316857
Drug: Orelabrutinib + Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib + Rifampin
Trial: NCT05316857
Drug: Orelabrutinib + Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orelabrutinib + Itraconazole
Trial: NCT05582538
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
Trial: NCT05582538
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg i.v. day 1 (q28)
Trial: NCT05582538
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/m2 i.v. day 1,8,15 (q28)
Trial: NCT04892446
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04892446
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered either SC or IV
Trial: NCT04892446
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04892446
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04892446
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered either SC or IV
Trial: NCT04892446
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT06091423
Drug: XELOX combined with Fruquintinib and Sintilimab
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
Trial: NCT05174806
Drug: Topical Pravibismane
RxNorm normalized name: Pravibismane
DrugBank: Pravibismane (DB17784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Pravibismane
Trial: NCT05509257
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
Trial: NCT06562816
Drug: Trypsin-Chymotrypsin
RxNorm normalized name: TRYPSIN-CHYMOTRYPSIN
DrugBank: Chymotrypsin (DB09375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100000 IU
Trial: NCT04523792
Drug: SUBLOCADE
RxNorm normalized name: Sublocade
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Trial: NCT05327530
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Trial: NCT05327530
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Trial: NCT05327530
Drug: M6223
RxNorm normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Trial: NCT05085002
Drug: Lerociclib + Letrozole or Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
Trial: NCT06572761
Drug: Combination of antibiotics
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
Trial: NCT06104683
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06572761
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal progesterone
Trial: NCT00850512
Drug: Zevalin
RxNorm normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12-week safety period for Zevalin
Trial: NCT03064282
Drug: papaverine
RxNorm normalized name: Papaverine
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: observation of symptoms
Trial: NCT05545397
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
Trial: NCT06128837
Drug: Irinotecan hydrochloride liposome Injection
RxNorm normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
Trial: NCT06128837
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
Trial: NCT06270225
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Trial: NCT06270225
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Trial: NCT06270225
Drug: Colchicine 0.5 mg
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 0.5mg/d Colchicine for 12 weeks.
Trial: NCT05575518
Drug: Optimised rifamycin
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: optimised dose rifampicin with or without moxifloxacin
Trial: NCT06069063
Drug: Zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
Trial: NCT04967430
Drug: Peginterferon Lambda-1A
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
Trial: NCT05427630
Drug: Sham Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis flower from which the THC and CBD have been extracted
Trial: NCT05171530
Drug: Lenvatinib plus taxane drugs
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA
Trial: NCT01539265
Drug: silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06512428
Drug: simmitinib plus irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
Trial: NCT06512428
Drug: irinotecan liposome
RxNorm normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan liposome 70 mg/m\^2 every 2 weeks
Trial: NCT06512428
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan 180mg/m\^2 every 2 weeks
Trial: NCT04309721
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
Trial: NCT05165394
Drug: NBI-1065846
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT06111326
Drug: Durvalumab injection
RxNorm normalized name: durvalumab Injection
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
Trial: NCT06211283
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fasted
Trial: NCT06211283
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fed
Trial: NCT04573777
Drug: Repatha
RxNorm normalized name: Repatha
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
Trial: NCT05424692
Drug: 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Trial: NCT04745832
Drug: Zandelisib
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
Trial: NCT04745832
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab IV 375 mg/m2 for 6 cycles
Trial: NCT04745832
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
Trial: NCT04745832
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
Trial: NCT06508983
Drug: pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
Trial: NCT06508983
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
Trial: NCT05134974
Drug: Phentolamine Ophthalmic Solution 0.75%
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Trial: NCT05134974
Drug: Phentolamine Ophthalmic Solution Vehicle
RxNorm normalized name: phentolamine Ophthalmic Solution
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentolamine Ophthalmic Solution Vehicle
Trial: NCT06485544
Drug: Adebrelimab + Etoposide + Platinum-based Therapy
RxNorm normalized name: platinum
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Trial: NCT06485544
Drug: Etoposide + Platinum-based Therapy
RxNorm normalized name: platinum
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment.
Trial: NCT05293938
Drug: Obeticholic Acid 5 MG
RxNorm normalized name: obeticholic acid 5 MG
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once daily, oral administration
Trial: NCT05293938
Drug: Obeticholic Acid 10 MG
RxNorm normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once daily, oral administration
Trial: NCT00001081
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05123287
Drug: PD-1 immune checkpoint blockades
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
Trial: NCT04978753
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;
Trial: NCT06665568
Drug: Intranasal ketamine hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
Trial: NCT05111249
Drug: Branaplam
RxNorm normalized name: Branaplam
DrugBank: Branaplam (DB14918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.